Anika Therapeutics Stock
Anika Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- United States
- CEO
- Stephen D. Griffin
- Employees
- 235
- Market cap
- $267 M
- IPO
- 03/05/1993
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced…
Anika Therapeutics stock: price history
1D
-3.4%
1W
+2.0%
1M
-4.1%
6M
+24.9%
YTD
+107.9%
1Y
+119.8%
2Y
-20.7%
5Y
-52.0%
10Y
-55.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~102% stronger price swings than usual
Ask the agents about Anika Therapeutics
Analyst assessment of Anika Therapeutics
PRICE TARGET LOW
US$21.00
CONSENSUS
US$21.00
MEDIAN
US$21.00
PRICE TARGET HIGH
US$21.00
0
STRONG BUY
4
BUY
3
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 30/07/2026
Anika Therapeutics stock metrics
P/E
-74.14
P/B
1.95
EV/EBITDA
92.76
RETURN ON EQUITY
2.4%
NET MARGIN
10.1%
DEBT/EQUITY
0.17
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.7%
FLOAT SHARES
12,542,012
AVG. DAILY VOLUME (30D)
90,405
Insider transactions (SEC)
Fischetti Gary P
Fischetti Gary P
Richard Stephen
HENNEMAN JOHN B III
Fischetti Gary P
Institutional holders
Comparable stocks
Frequently asked questions about Anika Therapeutics stock
What does Anika Therapeutics do?
Anika Therapeutics, Inc. is a company in the Healthcare sector, Medical - Specialties industry, headquartered in United States.
The CEO is Stephen D. Griffin, the company employs around 235 people.
The IPO was on 03/05/1993; the stock trades on NASDAQ under the ticker ANIK.
What do analysts say about Anika Therapeutics stock?
7 analysts rate the stock, the consensus is Buy (as of 30/07/2026).
The average price target is US$21.00, ranging from US$21.00 to US$21.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Anika Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 102% stronger than usual.
Does Anika Therapeutics pay a dividend?
No, Anika Therapeutics currently does not pay a dividend.
Which stocks are comparable to Anika Therapeutics?
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Eli Lilly and Company, Johnson & Johnson and AbbVie.
How can I get Anika Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Anika Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.